Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Wubi Shanyao Pill for moderate/high-risk IgA nephropathy
ChiCTR2100052079Phase 4Not yet recruiting
- Sponsor
- Zhejiang Provincial People's Hospital
- Start
- Sep 2021
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of wubi shanyao pill in IgA nephropathy (IgAN) (2 arms), sponsored by Zhejiang Provincial People's Hospital. Primary endpoint: 24-hour proteinuria change. Planned start Sep 2021; status: not yet recruiting.
02
Drugs
wubi shanyao pill
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on ChiCTR2100052079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100052079.